WHO ICTRP trial
CIGB-247-V vaccine in Age-Related Macular Degeneration, phase I-II randomized.
RPCEC00000189 · Registro Público Cubano de Ensayos Clínicos (RPCEC) · Not Recruiting
Key facts
| Trial ID | RPCEC00000189 |
|---|---|
| Public title | CIGB-247-V vaccine in Age-Related Macular Degeneration, phase I-II randomized. |
| Scientific title | Use of the CIGB-247-V vaccine candidate in the treatment of Age-Related Macular Degeneration. |
| Primary sponsor | Center for Genetic Engineering and Biotechnology (CIGB), in Havana. |
| Secondary sponsors | Not applicable |
| Registry | Registro Público Cubano de Ensayos Clínicos (RPCEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 1-2 |
| Countries | Cuba |
| Conditions | Age-Related Macular Degeneration. |
| Interventions | Group I (Control A): Intravitreal treatment with antibody Bevacizumab (Avastin®) (monthly scheme for one year). Group II (Control B): Intravitreal treatment with antibody Bevacizumab (Avastin®) (monthly schedule for 3 months and then as… |
| Registration date | Oct 11, 2014 |
| Target size | 66 |
| Secondary IDs | IG/CIGB-247I/DM/1301 |
| Registry page | rpcec.sld.cu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: